GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
P

Prince Pharmaceutical Co 6935.TWO · TWD

Health Care · Taipei Exchange · 🇹🇼 Taiwan

Compare

26.85

0.00%

Close of 9 Nov 2026, in TWD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Prince Pharmaceutical Co

Its shares trade on Taipei Exchange under the ticker 6935.TWO. It has been listed since 29 March 2023. In the fiscal year to 31 December 2025, it reported revenue of TWD 1.06bn and net income of TWD 96.3m. At that date it held total assets of TWD 1.50bn and shareholders' equity of TWD 838.7m.

Prince Pharmaceutical Co. Ltd. principally engages in the production of active pharmaceutical ingredients of Vitamin B1. The company is headquartered in Huwei, Yunlin. The company went IPO on 2023-03-29. The firm's main business is divided into ingredients business and health food business. The ingredients business currently consists of phlegm dispelling agents, vitamin B1 derivatives, and non-steroidal anti-inflammatory drugs. The health food business is mainly engaged in the original equipment manufacturer (OEM) and original design manufacturer (ODM) of health food products, providing a series of integrated services from product formulation design, research and development to the production and packaging of various dosage forms. The firm sells its products mainly in domestic and overseas markets, including Japan and Korea.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
29 Mar 2023

Leadership

Pay as last reported

  • Qida LiChairman of the Board, General Manager
  • Changxian YuDeputy General Manager- Health Products Division, Director
  • Yingru JinCorporate Governance Officer
  • Yinglin HuangDirector
  • Zhiyi LuDirector
  • Ms. Chin-Hua ChengIndependent Director
  • Ms. Yunyao ChengIndependent Director
  • Debin TaoIndependent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Produces active pharmaceutical ingredients for Vitamin B1
  • Operates in both ingredients and health food business sectors
  • Sells products in domestic and international markets including Japan and Korea

Weaknesses

  • Limited to Vitamin B1 derivatives and specific drug categories
  • IPO occurred in 2023, indicating recent market entry
  • Relies on OEM and ODM for health food business

Opportunities

  • Expansion into new markets beyond Japan and Korea
  • Growth potential in health food OEM/ODM services
  • Increasing demand for Vitamin B1 derivatives

Threats

  • Dependence on specific product lines like Vitamin B1
  • Competition in pharmaceutical and health food industries
  • Recent IPO may face market volatility

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.